Treatment Information

Back

Rectal Cancer treatment details. Biologic therapy.

Memorial Sloan-Kettering Cancer Center, New York, New York, United States.

Survival: monthsCountry:United States
Toxiciy Grade:3City/State/Province:New York, New York
Treatments:Biologic therapyHospital:Memorial Sloan-Kettering Cancer Center
Drugs:Journal:Link
Date:Jul 2002

Description:

Patients: Twenty-one patients with metastatic colorectal cancer were enrolled in this Phase II study. Twenty of the twenty-one patients had received prior 5-FU therapy and all twenty-one had received prior irinotecan therapy.

Treatment: Treatment comprised a new agent SCH 66336 which is a molecular inhibitor of Farnesyl protein transferase (FPTase). FPTase is an enzyme that is responsible for a critical post-translational modification of Ras.

Toxicity: Grade 3 toxicities included: diarrhea, fatigue, nausea, anemia, increased serum creatinine and increased bilirubin.

Results: There were no major objective responses.

Support: Two of the eleven authors of the study are affiliated with Schering-Plough Corporation.

Correspondence: Dr. S. Sharma




Back